Crizotinib inhibition of ROS1-positive tumours in advanced non-small-cell lung cancer: a Canadian perspective

摘要: The ros1 kinase is an oncogenic driver in non-small-cell lung cancer (nsclc). Fusion events involving the ROS1 gene are found 1%-2% of nsclc patients and lead to deregulation a tyrosine kinase-mediated multi-use intracellular signalling pathway, which then promotes growth, proliferation, progression tumour cells. fusion distinct molecular subtype nsclc, independently other recognized mutations, it predominantly identified younger (<50 years age), women, never-smokers, with adenocarcinoma histology. Targeted inhibition aberrant crizotinib associated increased progression-free survival (pfs) improved quality-of-life measures. As sole approved treatment for ROS1-rearranged has been demonstrated, through variety clinical trials retrospective analyses, be safe, effective, well-tolerated, appropriate having rearrangement. Canadian physicians endorse current guidelines recommend that all nonsquamous advanced regardless characteristics, tested Future integration multigene testing panels into standard care could allow efficient cost-effective comprehensive nsclc. If rearrangement found, crizotinib, preferably first-line setting, constitutes care, options being investigated, as appropriate, should resistance develop.